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AbstrAct
background Acute hypoxic respiratory failure (AHRF) is 
associated with significant acute mortality. It is unclear 
whether later mortality is predominantly driven by pre-
existing comorbid disease, the acute inciting event or is 
the result of AHRF itself.
Methods Observational cohort study of elderly 
US Health and Retirement Study (HRS) participants 
in fee-for-service Medicare (1998–2012). Patients 
hospitalised with AHRF were matched 1:1 to otherwise 
similar adults who were not currently hospitalised and 
separately to patients hospitalised with acute inciting 
events (pneumonia, non-pulmonary infection, aspiration, 
trauma, pancreatitis) that may result in AHRF, here 
termed at-risk hospitalisations. The primary outcome was 
late mortality—death in the 31 days to 2 years following 
hospital admission.
results Among 15 075 HRS participants, we identified 
1268 AHRF and 13 117 at-risk hospitalisations. AHRF 
hospitalisations were matched to 1157 non-hospitalised 
adults and 1017 at-risk hospitalisations. Among patients 
who survived at least 30 days, AHRF was associated 
with a 24.4% (95%CI 19.9% to 28.9%, p<0.001) 
absolute increase in late mortality relative to adults 
not currently hospitalised and a 6.7% (95%CI 1.7% to 
11.7%, p=0.01) increase relative to adults hospitalised 
with acute inciting event(s) alone. At-risk hospitalisation 
explained 71.2% of the increased odds of late mortality, 
whereas the development of AHRF itself explained 
28.8%. Risk for death was equivalent to at-risk 
hospitalisation beyond 90 days, but remained elevated 
for more than 1 year compared with non-hospitalised 
controls.
conclusions In this national sample of older 
Americans, approximately one in four survivors with 
AHRF had a late death not explained by pre-AHRF 
health status. More than 70% of this increased risk was 
associated with hospitalisation for acute inciting events, 
while 30% was associated with hypoxemic respiratory 
failure.
IntroductIon
Acute hypoxic respiratory failure (AHRF) is a 
leading cause of intensive care unit admission1 2 
with high acute mortality.1 However, the impact of 
AHRF on late mortality (death in the 31 days to 
2 years after hospital admission) is unclear. Studies 
with longer-term follow-up indicate that patients 
continue to die at a high rates after surviving hospi-
talisation for acute respiratory distress syndrome 
(ARDS, a severe form of AHRF),3 4 but without a 
comparison cohort, we cannot determine whether 
this late mortality is the result of pre-existing 
comorbid disease versus a direct effect of AHRF. An 
older study suggests that patients surviving ARDS 
do not have increased risk of late mortality relative 
to patients surviving hospitalisation for inciting 
events alone—but was not powered to detect 
effects smaller than a 14% absolute difference.5 
With declining in-hospital mortality,6–8 AHRF-re-
lated mortality may now be shifted to the posthos-
pital period. Other critical illnesses, such as sepsis9 
and delirium,10 are associated with increased late 
mortality. Thus, we hypothesised that AHRF may 
also increase patients’ risk for late mortality.
Understanding whether patients who survive 
AHRF acutely face increased risk for late death is 
important for (1) measuring the overall burden of 
AHRF-related mortality, (2) determining whether 
AHRF is associated with prolonged pathobiolog-
ical derangements that may be amenable to treat-
ment, (3) informing the timing of interventions to 
improve long-term survivorship after AHRF, (4) 
selecting clinical trial end-points and (5) under-
standing the prognosis of patient surviving  AHRF.
To address these questions, we compared patients 
hospitalised with AHRF to two controls: adults 
not currently hospitalised and patients hospital-
ised with acute inciting events that may result in 
AHRF—pneumonia, non-pulmonary infection, 
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Key messages
What is the key question?
 ► To examine whether late mortality after acute 
hypoxic respiratory (AHRF) is predominantly 
driven by pre-existing comorbid disease, 
the acute inciting event that precipitates 
respiratory failure (pneumonia, non-pulmonary 
infection, aspiration, trauma, pancreatitis) or 
the development of respiratory failure itself.
What is the bottom line?
 ► One in four survivors of AHRF has a late death 
that is not explained by pre-AHRF health 
status, but 70% of this increased risk for late 
death is due to the acute inciting events, 
while only 30% is due to the development of 
respiratory failure itself.
Why read on?
 ► We studied a large national cohort with 
longitudinal data to examine late mortality 
after AHRF hospitalisation relative to two 
carefully matched control groups—patients 
hospitalised with acute events that may 
precipitate AHRF and non-hospitalised adults.
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aspiration, trauma or pancreatitis. These comparisons allow us 
to determine both (1) the excess late mortality of an episode of 
AHRF and (2) the incremental excess late mortality of AHRF, 




We studied participants in the US Health and Retirement Study 
(HRS), a longitudinal cohort of 37 000 adults aged 51 and above 
in 23 000 households, ongoing since 1992.11 The study uses a 
multistage probability sample to identify participants.11 The 
sociodemographic and racial distribution is broadly representa-
tive of the older US population.12–14 The cohort is interviewed 
every 2 years with a follow-up rate consistently over 90%.11 
Survey questions focus on wealth, health, cognition and employ-
ment.11 Data are linked to federal health insurance (Medicare) 
claims.11 Participants provide informed consent on enrolment to 
HRS and again for linkage to Medicare insurance claims. We 
considered fee-for-service Medicare beneficiaries aged ≥65 who 
took part in at least one survey during 1998–2010 for inclusion 
in the study.
study cohorts
We identified three study cohorts. The primary cohort was 
patients hospitalised with AHRF. The comparison cohorts were 
(1) adults not currently in the hospital (non-hospitalised adults) 
and (2) patients hospitalised with an acute inciting event that 
may cause AHRF (at-risk hospitalisations).
We defined AHRF hospitalisations pragmatically in admin-
istrative claims as (1) diagnostic codes for one or more acute 
inciting events that may result in AHRF—pneumonia, non-pul-
monary infection, aspiration, trauma or pancreatitis and (2) 
respiratory failure—a procedural code for invasive mechanical 
ventilation and/or an explicit diagnosis code of acute respiratory 
failure (online supplementary table S1). We validated this claims-
based AHRF definition in the University of Michigan Health 
System. It had a positive predictive value of 81.4% (95%CI 
72.3% to 88.6%) and a negative predictive value of 91.9% (95% 
CI 90.0% to 93.4%) when compared with a clinical AHRF defi-
nition of PaO2/FIO2 <300 while on ≥40% fraction of inspired 
oxygen (online supplementary appendix 1).
We defined at-risk hospitalisations as those with diagnostic 
codes for one or more acute inciting events that may result in 
AHRF, but no diagnostic code for either respiratory failure or 
mechanical ventilation. We excluded hospitalisations with diag-
nostic codes for stroke or chronic respiratory failure from both 
hospitalised cohorts, as these diagnoses suggest a cause for respi-
ratory failure other than an acute pulmonary process.
The cohort of non-hospitalised adults was not in the hospital 
at the time point that they were matched, but no exclusions were 
placed on this cohort being admitted to the hospital either before 
or after the date of match. (Further details of this matching 
approach are described in a previous publication.9)
Matching
At the time of each HRS survey, we estimated each participant’s 
risk of having an AHRF hospitalisation in the next 2 years using 
multiple logistic regression. We selected the following predictor 
variables based on previous research and/or clinical experience 
suggesting it is an important risk factor for AHRF, or acute 
hospitalisation15
 ► Demographics: age, self-reported race and ethnicity, 
gender, partnership status.
 ► Economic status: wealth (sum of all assets and debts) 
standardised to 2013 $ using the annual gross domestic 
product price index,16 previous or current use of food 
stamps (a government assistance programme for low-
income families and individuals).
 ► Healthcare utilisation: number of hospitalisations in 
the prior year, AHRF hospitalisation in the prior year, 
residence in a nursing home.
 ► Health status: limitations of five activities and six 
instrumental activities of daily living (IADLs/ADLs), self-
rating of health, body mass index (BMI).
 ► Comorbidity burden: 17 Charlson comorbidities.17 18
Limitations of ADLs, IADLs, self-reported health, government 
assistance and BMI were missing in 5.6%, 0.1%, 0.1%, 0.5% and 
1.4%, respectively, and these values were imputed using multiple 
imputation with chained equations and five imputations.19 Other 
covariates were present for the entire population. We considered 
select interactions (gender and partnership) and non-linear forms 
(age) based on a priori knowledge of the relations between the 
predictors and the likelihood of hospitalisation.20
We matched patients in the AHRF cohort 1:1 to patients in the 
at-risk hospitalisation cohort by age, percentile risk for AHRF 
hospitalisation, number of hospitalisations in the year prior to 
index admission, AHRF hospitalisation in the prior year, acute 
precipitating events during index hospitalisation (pneumonia, 
non-pulmonary infection, aspiration, trauma and pancreatitis) 
and other conditions during the index hospitalisation that may 
contribute to respiratory failure (congestive heart failure and 
asthma/chronic obstructive pulmonary disease) using coarsened 
exact matching.21
We examined the balance of each covariate (those directly 
matched, as well as those included within the multivariable risk 
for AHRF hospitalisation) between the hospitalised cohorts 
using Χ2 and t tests, as appropriate, without consideration of 
any outcome.22 We then re-matched the hospitalised cohorts 
including any variables that were unbalanced on the initial 
match. We then re-examined and confirmed covariate balance 
before examining any results. We matched patients in the AHRF 
cohort 1:1 in adults in the non-hospitalised cohort again using 
an iterative process to ensure covariate balance. Further details 
are provided in the online supplementary appendix 2.
outcomes and statistical analysis
Our primary outcome of interest was late mortality, defined as 
death in the 31 days to 2 years following AHRF hospital admis-
sion, at-risk hospital admission or the date of match, depending 
on the cohort. All patients were followed to death, or for 2 
years. We used multivariable Cox proportional hazards models 
to calculate the HR for late mortality, adjusted for age, gender 
and propensity of AHRF. In addition, we used multivariable 
logistic regression models in order to calculate adjusted propor-
tions of mortality. The technique of matching patients, then also 
adjusting for potential confounders using regression, is known 
as ‘doubly-robust’ estimation because it combines two methods 
for reducing bias and is less sensitive to misspecification.23 24 In 
the primary analysis, we accounted for the clustering of hospital-
isations within people using clustered robust standard errors.25 
This approach corrects standard errors so that significance tests, 
which assume independence of observations, are still valid.
Beyond measuring risk of late mortality overall, we also 
measured risk of death at multiple time intervals (0–30 days, 
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Figure 1 Cohort flow. 
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31–90 days, 181 days–1 year and 1–2 years) to examine how 
long excess mortality persists after AHRF. In addition, we 
present the risk of mortality over time in a hazard plot. To esti-
mate the proportion of late mortality due to hospitalisation for 
the acute inciting invent(s) versus the development of AHRF, 
we examined the ratio of logistic regression coefficients among 
AHRF hospitalisations that were matched to both controls (as 
described in the online supplementary appendix 2).
We performed several exploratory analyses. First, we examined 
whether excess late mortality after AHRF differed by type of acute 
inciting event, age, sex, self-rating of health, comorbidity burden, 
pre-AHRF functional limitations and nursing home residence. 
Second, we examined risk of late death separately for earlier (1998–
2005) versus later hospitalisations (2006–2012), since management 
of AHRF has changed over time. Third, we examined risk of late 
death among patients with no hospitalisation for AHRF in the prior 
year. Fourth, we examined the proportion of patients surviving to 
31 days who had a subsequent hospitalisation, as well as the subset 
who survived to 2 years. Fifth, we examined the principal diagnosis 
category26 of the final hospitalisations (a proxy for cause of death27) 
among patients with AHRF with a late death.
We performed five sensitivity analyses, described in the 
online supplementary appendix 2. Conceptually, sensitivity 
analyses 1–3 used alternative approaches to account for clus-
tering of observations within people, since each person may 
have multiple hospitalisations and/or times of non-hospital-
isation. Sensitivity analyses 4 and 5 used alternate approaches 
to matching. We conducted all analyses with Stata MP V. 14 
(StataCorp, College Station, TX). We used two-sided hypoth-
esis testing and set significance at p<0.05.
results
From 15 075 HRS participants with Medicare linkage and at 
least one survey completed in 1998–2010, we identified 1268 
AHRF hospitalisations, 13 117 at-risk hospitalisations and 
15 033 non-hospitalised adults (figure 1).
For the 1238 AHRF hospitalisations, patients were elderly 
(median age 79), 54.5% were female, 80.2% were white, 11.2% 
were nursing home residents, with a median of one functional 
limitations and two medical comorbidities (table 1). Over 60% of 
patients rated their health as fair or poor. Risk factors for AHRF 
were non-pulmonary infection (65.4%), pneumonia (45.0%), aspi-
ration (18.0%), trauma (5.6%) and pancreatitis (1.3%). 33.5% had 
multiple risk factors.
Mortality was high: 42.7% at 30 days, 65.5% at 1 year and 
73.3% at 2 years. Among the 727 patients who survived to 
day 31, 131 (18.0%) died by 90 days and 389 (53.5%) died by 
2 years. Of the 389 patients who died during day 31 to 2 years, 
all but 23 (5.9%) were discharged from the hospital prior to 
death.
We were able to match 1157 AHRF hospitalisations (91.5% 
of all AHRF hospitalisations) to non-hospitalised adults, and 
1017 AHRF hospitalisations (80.2%) to at-risk hospitalisations 
(figure 1, online supplementary tables S2 and S3). Nine hundred 
and fifty-two AHRF hospitalisations (75.1%) were matched 
to both an at-risk hospitalisation and a non-hospitalised adult; 
mortality for these double-matched cohorts is presented in 
online supplementary table S4. AHRF was associated with mark-
edly increased acute mortality relative to matched non-hospi-
talised adults (adjusted HR (aHR) for 30-day mortality: 30.5; 
95% CI 19.8 to 47.1) and matched at-risk hospitalisations 
(aHR for 30-day mortality: 4.0; 95% CI 3.3 to 4.8). The risk of 
mortality waned with time (figure 2), becoming equivalent to 
at-risk hospitalisation around day 90. However, risk remained 
slightly elevated compared with non-hospitalised controls to 
beyond 1 year.
Compared with adults not in the hospital matched on all 
baseline characteristics, patients with AHRF experienced a 
24.4% (95% CI 19.9% to 28.9%) absolute increase (or 1.9-fold 
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table 1 Baseline characteristics of AHRF cohort (n=1268)
demographics
  Age, years, median (IQR) 79 (72–85)
  Male, n (%) 589 (46.5%)
  Race, n (%)
   White/Caucasian 1017 (80.2%)
   Black/African American 220 (17.4%)
   Other 31 (2.4%)
  Hispanic, n (%) 96 (8.4%)
  Married or partnered, n (%) 591 (46.6%)
economic status
  Total wealth
   Quintile 5 positive assets 172 (13.7%)
   Quintile 4 positive assets 186 (14.7%)
   Quintile 3 positive assets 186 (14.7%)
   Quintile 2 positive assets 242 (19.2%)
   Quintile 1 positive assets 324 (25.7%)
   Net negative or zero assets 150 (11.9%)
  Government assistance 120 (9.6%)
Pre-AhrF health status
  Charlson Comorbidity Index, median (IQR) 2 (0–4)
   Congestive heart failure 387 (30.5%)
   Dementia 97 (7.7%)
  IADL/ADL limitations, median (IQR) 1 (0–5)
  Self-rating of health, n (%)
   Excellent 31 (2.5%)
   Very good 150 (11.9%)
   Good 300 (23.7%)
   Fair 391 (30.9%)
   Poor 394 (31.1%)
  Body mass index, n (%)
   Very severely obese 57 (4.6%)
   Severely obese 73 (5.9%)
   Obese 164 (13.2%)
   Overweight 355 (28.6%)
   Normal 499 (40.2%)
   Underweight 94 (7.6%)
  Multivariable risk for AHRF 5.9% (3.4%–10.7%)
Pre-AhrF healthcare use
  Hospitalisations in prior year, median (IQR) 1 (0–2)
  AHRF in prior year, n (%) 151 (11.9%)
  Residence in a nursing home, n (%) 142 (11.2%)
hospitalisation diagnoses
  Risk factor for direct AHRF 766 (60.4%)
   Pneumonia 570 (45.0%)
   Aspiration 228 (18.0%)
  Risk factor for indirect AHRF 890 (70.2%)
   Non-pulmonary infection 834 (65.8%)
   Trauma 71 (5.6%)
   Pancreatitis 16 (1.3%)
AHRF, acute hypoxic respiratory failure; IADL, instrumental activities of daily living.
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relative increase) in late mortality. Adjusted 31-day to 2-year 
mortality was 52.4% (95% CI 48.5% to 56.2%) in patients 
with AHRF surviving to at least 31 days versus 28.0% (95% 
CI 25.4% to 30.6%) among matched non-hospitalised patients 
who survived to at least 31 days (aHR for late mortality: 2.5, 
p<0.001) (figure 3a, online supplementary table 5). Adjusted 
91-day to 2-year mortality was 42.0% (95% CI 37.9% to 
46.2%) in survivors with AHRF versus 25.9% (95% CI 23.3% 
to 28.6%) in matched non-hospitalised patients, p<0.001. The 
higher mortality in the AHRF cohort persisted for the full 2-year 
follow-up period. Among patients with AHRF who survived to 
1 year, the adjusted 2-year mortality was 21.0% (95% CI 17.0% 
to 25.0%) versus 14.9% (95% CI 12.6% to 17.2%) in their 
controls who were not in the hospital at the time of matching 
(aHR for 2-year mortality: 1.4, p=0.006).
Compared with matched patients hospitalised with the same 
acute inciting event, patients with AHRF experienced a 6.7% 
(95% CI 1.7% to 11.7%) absolute increase (1.15-fold relative 
increase) in late mortality (aHR for late mortality: 1.2, p=0.01) 
(figure 3b, online supplementary table S5). The increased risk for 
late mortality did not persist beyond 90 days. Among those who 
survived to at least 91 days, risk mortality at 2 years was indistin-
guishable from patients surviving hospitalisation for AHRF risk 
factors alone (aHR for 2-year mortality=1.1, p=0.23).
Among patients with AHRF who survived to day 31 and were 
matched to both an at-risk hospitalisation and a non-hospital-
ised adult, at-risk hospitalisation accounted for 71.2% (95% CI 
52.7% to 89.6%) of the increased odds of late mortality, whereas 
the development of AHRF itself accounted for 28.8% (95% CI 
10.4% to 47.3%) of the increased odds of late mortality.
In all five sensitivity analyses, the point estimates of ORs for 
late mortality relative to non-hospitalised adults and relative to 
patients with an at-risk hospitalisation were similar to the ORs 
in the primary analyses (online Supplementary table S6). Statis-
tical significance was lost, however, in two instances due to the 
smaller sample sizes in the sensitivity analysis. Results were also 
similar for earlier versus later hospitalisations.
In stratified analysis, the excess late (31 days to 2 years) 
mortality after AHRF was relatively constant across patient 
subgroups defined by type of acute inciting event, sex, comor-
bidity burden, functional limitations, self-rating of health and 
nursing home residence (Figure 4 online supplementary figure 
S1). However, the incremental effect of AHRF versus at-risk 
hospitalisation on late mortality was greater in patients ≥80 
years versus patients<80 years (figure 4). Risk for late death 
was similar when limiting the analysis to earlier hospitalisation 
(1998–2005), later hospitalisation (2006–2012)and patients 
without a hospitalisation for AHRF in the prior year (online 
supplementary table S7 and S8).
Re-hospitalisation was more common in AHRF versus 
comparison cohorts (online supplementary table S9 and 
figure S2). Of the 398 patients with AHRF who experienced 
a late death following AHRF, 290 (72.9%) were re-hospi-
talised prior to their death. The most common hospitalisa-
tion diagnoses prior to death were sepsis (16.6% of terminal 
hospitalisations), respiratory failure (15.2%), congestive 
heart failure (9.0%), aspiration pneumonitis (6.6%) and 
pneumonia (5.2%).
dIscussIon
In this national cohort of older Americans, late mortality was 
substantially increased after AHRF relative to non-hospitalised 
adults. Among patients who survived to at least day 31 after hospital 
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Figure 2 Risk of death over time. The risk of death over time is shown for the AHRF cohort (in red), non-hospitalised cohort (in green) and at-risk 
cohort (in blue). The shaded area represents the 95% CI. AHRF, acute hypoxic respiratory failure.
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admission for AHRF, more than half died within the next 2 years. 
This high rate of late mortality was not explained by age, sociode-
mographics or health status prior to AHRF. Compared with adults 
not in the hospital who were indistinguishable on a variety of poten-
tial confounders prior to acute illness, patients surviving AHRF 
have a nearly 25% absolute increase in late mortality.
The majority (70%) of the late mortality after AHRF was 
explained by hospitalisation for the acute inciting event(s), while 
a minority (30%) was explained by the development of AHRF. 
Compared with patients hospitalised with acute inciting event(s) 
but without AHRF, those with AHRF had a 7% absolute increase 
in late mortality. Among hospitalised patients who survived for 
at least 90 days; however, the risk for subsequent mortality was 
indistinguishable. Subgroup analysis suggested that the incre-
mental effect of AHRF on late mortality may be concentrated in 
the oldest patients.
Prior studies have shown that ARDS is associated with signifi-
cantly increased early (30 day) mortality compared with hospi-
talisation for inciting events that may lead to ARDS, such as 
hospitalisation for sepsis28 and trauma.29 Our findings on early 
mortality are similar. Compared with patients who were hospi-
talised for acute inciting events alone, AHRF was associated 
with a fivefold relative increase, or approximately 30% absolute 
increase in 30-day mortality in our study. This can be consid-
ered as a form of ‘positive control’, in that it confirms that our 
AHRF population is distinct from the non-AHRF hospitalised 
patients.
We were able to identify just one prior study that examined late 
mortality of survivors with ARDS or AHRF relative to matched 
controls. This study of patients treated in the mid-1990s found 
no difference in late mortality between 127 survivors with ARDS 
and 127 controls matched by acute inciting event (sepsis or 
trauma), illness severity and admission half-year.5 However, the 
study had limited power, and so an important difference in late 
mortality (as large as 13%) could not be ruled out. With a larger 
sample, our study was able to detect a small increase in risk of 
late mortality after AHRF relative to hospitalisations for acute 
inciting events alone, but approximately 70% the excess risk for 
late mortality after AHRF was explained by at-risk hospitalisa-
tion.
While it may seem counterintuitive for survivors with AHRF 
to experience similar late mortality as survivors of less severe 
illness, this phenomenon has precedent. Elderly survivors of 
in-hospital cardiac arrest have only modestly lower 2-year 
group.bmj.com on August 11, 2017 - Published by http://thorax.bmj.com/Downloaded from 
6 Prescott HC, et al. Thorax 2017;0:1–8. doi:10.1136/thoraxjnl-2017-210109
Figure 3 Kaplan-Meier survival curves for AHRF cohorts versus matched comparison cohorts showing long-term survival of patients who survived 
at least 30 days after this match day. The proportion surviving over time is shown for the AHRF cohort (in red), non-hospitalised cohort (in green) and 
at-risk cohort (in blue). The shaded area represents the 95% CI.AHRF, acute hypoxic respiratory failure.
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survival rates compared with patients who survive a hospital-
isation for heart failure, and the survival curves converge at 
3 years30.
The contrast between the present results showing a small 
degree of excess late mortality after AHRF relative to matched 
hospitalised controls and previous work using a similar meth-
odology for late mortality after sepsis9 is intriguing. It raises the 
possibility that our focus on mechanical ventilation as the key 
risk factor in mediating late harm in patients surviving the ICU 
may be too narrow. For example, mechanical ventilation is often 
a key inclusion criteria for post-ICU rehabilitation studies,31 but 
may not target the most appropriate population. The contrast 
also suggests that the inflammation and multi-organ failure 
associated with ventilator-induced lung injury32 may resolve 
faster than the inflammation and immune-suppression that 
follows sepsis.33 Future epidemiological and translational studies 
are needed to better understand the duration and recovery of 
these pathobiological derangements—and how the natural 
history differs between AHRF and sepsis.
Our study should be interpreted in the context of several 
limitations. First, this is an observational study, so cannot prove 
causation. We have attempted to control for confounding as best 
as possible through matching and regression adjustment, as well 
as by studying a cohort with prospectively collected data on a 
range of potential confounders. Second, we ascertained AHRF 
by International Classification of DIseases, Ninth Revision, 
group.bmj.com on August 11, 2017 - Published by http://thorax.bmj.com/Downloaded from 
7Prescott HC, et al. Thorax 2017;0:1–8. doi:10.1136/thoraxjnl-2017-210109
Figure 4 Absolute excess late mortality of AHRF versus at-risk hospitalisations, stratified by subgroup. AHRF, acute hypoxic respiratory failure.
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Clinical Modification (ICD-9-CM) coding for acute inciting 
events and respiratory failure. There may have been misclassi-
fication in both directions between at-risk and AHRF hospital-
isations, but the negative and positive predictive values from our 
validation suggest that the degree of misclassification is likely 
small. Third, our study spanned a period of 15 years when treat-
ment for AHRF changed. However, when limiting our analysis to 
only early or late hospitalisations, the associations were similar. 
Fourth, we were not able to examine the subset of patients with 
AHRF and ARDS because there is no reliable way to identify 
ARDS in administrative claims. Nonetheless, we believe AHRF 
to be a clinically meaningful study population,34 and postulate 
that our findings are reflective of ARDS patients as well. Fifth, 
we excluded patients aged <65 years because our study relied on 
Medicare claims, and only limited groups aged under 65 qualify 
for Medicare coverage.
Our study has several strengths. First, we believe that it is 
the only recent study to examine the excess late mortality asso-
ciated with AHRF. Second, by examining a national cohort 
with detailed survey and claims data, we were able to achieve 
robust control for confounding. Third, by comparing patients 
with AHRF with two controls, we were able to disentangle the 
proportion of excess mortality related to hospitalisations for 
acute inciting events versus the development of AHRF. Finally, 
our findings were robust to several sensitivity analyses.
conclusIon
In a national cohort of older Americans, we have shown that 
AHRF is associated with a high rate of late mortality that is not 
explained by health status before AHRF. However, more than 
70% of the excess risk for late mortality is explained by hospi-
talisation for an acute inciting event, not hypoxemic respiratory 
failure.
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